Integrating Novel Metabolomics Biomarkers with Multi‐modal Risk Factors in Predicting Mild Cognitive Impairment and Alzheimer's Disease

New molecular biomarkers (from both blood and saliva) perform strongly when integrated into databases with established AD biomarkers and risk factors. Implications include (1) enhancing identification of early mechanistic pathways, (2) importance of conducting integrative and interactive biomarker analyses, especially data-driven, and (3) potential for non-invasive salivary biomarkers for promoting assessment accessibility across diverse communities.